[1] Heidari R, Niknahad H, Jamshidzadeh A, et al. Factors affecting drug-induced liver injury: antithyroid drugs as instances. Clin Gastroenterol H, 2014, 20:237-248.
[2] Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol, 2001, 96:165-169.
[3] Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. In J Pediatr Endocrinol, 2009, 2009:132041.
[4] Karras S, Tzotzas T, Krassas GE. Toxicological considerations for antithyroid drugs in children. Expert Opin Drug Metab Toxicol, 2011, 7:399-410.
[5] Calkic L, Bajramovic-Omeragic L. Relationship of recovered hepatitis B infection with appearance of toxic propylthiouracil hepatitis. Med Glas (Zenica), 2017, 14:79-84.
[6] Miyamura T, Kanda T, Minemura S, et al. Acute liver failure associated with propylthiouracil in a pregnant 26-year-old woman. Case Rep Gastroenterol, 2013, 7:240-244.
[7] Benyounes M, Sempoux C, Daumerie C, et al. Propylthiouracil induced severe liver toxicity an indication for alanine aminotransferase monitoring World J Gastroenterol, 2006, 12:6232-6234.
[8] Wang MT, Lee WJ, Huang TY, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol, 2014, 78:619-629.
[9] Pagadala MR, Zein CO, Dasarathy S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci, 2012, 57:528-534.
[10] Ledda-Columbano GM, Perra A, Concas D, et al. Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma. Toxicol Pathol, 2003, 31:113-120.
[11] Chen RN, Huang YH, Yeh CT, et al. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res, 2008, 68:1697-1706.
[12] Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42:987-1000.
[13] Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol, 1997, 37:91-117.
[14] Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res : an official journal of the American Association for Cancer Research, 2009, 15:7361-7367.
[15] Lee HC, Wei YH. Mitochondrial role in life and death of the cell. J Biomed Sci, 2000, 7:2-15.
[16] Mitchell SC, Smith RL. Mitchell SC, et al. A physiological role for flavin-containing monooxygenase (FMO3) in humans? Xenobiotica, 2010, 40:301-305.
[17] Rivkees SA. 63 years and 715 days to the "boxed warning": unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol, 2010, 2010
[18] Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab, 2002, 3:367-377.
[19] Primeggia J, Lewis JH. Gone (from the Physicians' desk reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring. J Natil Med Assoc, 2010, 102:531-534. |
